chrisvoncsefalvay/vaers-narrative-generation huggingface dataset:
Age: 74.0
Sex: M
Vaccine: COVID19
Symptoms: Tenderness
Clinical narrative: right breast has gotten enlarged; right nipple hurts; right nipple hard as a rock; pain in the right breast; sensitive and tender; sensation was located on the nipple and felt sensitive and tender; This spontaneous case was reported by a consumer and describes the occurrence of BREAST PAIN (pain in the right breast), TENDERNESS (sensitive and tender), SENSORY DISTURBANCE (sensation was located on the nipple and felt sensitive and tender), GYNAECOMASTIA (right breast has gotten enlarged) and NIPPLE PAIN (right nipple hurts) in a 74-year-old male patient who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination. The occurrence of additional non-serious events is detailed below.     The patient's past medical history included Breast cancer in 1982 and Mastectomy bilateral (Tests results showed benign condition and no breast cancer.) in 1982. Concomitant products included SPIRONOLACTONE for an unknown indication.   On 24-Feb-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 24-Mar-2021, received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) dosage was changed to 1 dosage form. On 28-Mar-2021, the patient experienced BREAST PAIN (pain in the right breast), TENDERNESS (sensitive and tender) and SENSORY DISTURBANCE (sensation was located on the nipple and felt sensitive and tender). On an unknown date, the patient experienced GYNAECOMASTIA (right breast has gotten enlarged), NIPPLE PAIN (right nipple hurts) and INDURATION (right nipple hard as a rock). At the time of the report, BREAST PAIN (pain in the right breast), TENDERNESS (sensitive and tender), SENSORY DISTURBANCE (sensation was located on the nipple and felt sensitive and tender), GYNAECOMASTIA (right breast has gotten enlarged), NIPPLE PAIN (right nipple hurts) and INDURATION (right nipple hard as a rock) outcome was unknown. Not Provided          The patient reported that he was on several maintenance medications.  On an unspecified date, the heart doctor told the patient that the he had other patients who used spironolactone and experienced the same symptoms as him and that the suspect drug could be spironolactone.  The patient reported that he did not take any medications for treatment of the symptoms and that the tests came back negative. concomitants were provided. no treatment medication were provided.   This case was linked to MODERNATX, INC.-MOD-2021-101868 (E2B Linked Report).   Most recent FOLLOW-UP information incorporated above includes: On 15-Jun-2021: New events right nipple hurts, right nipple hard as rock and right breast has gotten enlarged.; Sender's Comments:  MODERNATX, INC.-MOD-2021-101868:cross linked case
Age: 46.0
Sex: M
Vaccine: COVID19
Symptoms: Influenza
Clinical narrative: flu; This spontaneous case was reported by a consumer and describes the occurrence of INFLUENZA (flu) in a 46-year-old male patient who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     No Medical History information was reported.    On 05-Apr-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 29-Apr-2021, the patient experienced INFLUENZA (flu). The patient was treated with DEXTROMETHORPHAN HYDROBROMIDE, DOXYLAMINE SUCCINATE, EPHEDRINE SULFATE, ETHANOL, PARACETAMOL (NYQUIL) for Flu, at a dose of 1 dosage form. At the time of the report, INFLUENZA (flu) outcome was unknown.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.   For mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular), the reporter did not provide any causality assessments.
Sex: M
Vaccine: COVID19
Symptoms: Drug ineffective, Vaccination site rash
Clinical narrative: no antibodies developed from the COVID vaccine; rash at injection site after first dose; This spontaneous case was reported by a consumer and describes the occurrence of DRUG INEFFECTIVE (no antibodies developed from the COVID vaccine) and VACCINATION SITE RASH (rash at injection site after first dose) in a 78-year-old male patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 013L20A) for COVID-19 vaccination.     Concurrent medical conditions included Multiple sclerosis (primary progressive). Concomitant products included FAMPRIDINE (AMPYRA) and OCRELIZUMAB (OCREVUS) for Multiple sclerosis, MOMETASONE FUROATE (ASMANEX), SALMETEROL XINAFOATE (SEREVENT), MIRABEGRON (MYRBETRIQ), ATORVASTATIN and TAMSULOSIN HYDROCHLORIDE (FLOMAX RELIEF) for an unknown indication.    On 15-Jan-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 15-Jan-2021, the patient experienced VACCINATION SITE RASH (rash at injection site after first dose). On an unknown date, the patient experienced DRUG INEFFECTIVE (no antibodies developed from the COVID vaccine). The patient was treated with PARACETAMOL (TYLENOL) ongoing since an unknown date at an unspecified dose and frequency. At the time of the report, DRUG INEFFECTIVE (no antibodies developed from the COVID vaccine) and VACCINATION SITE RASH (rash at injection site after first dose) outcome was unknown.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.   For mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular), the reporter did not provide any causality assessments.   Concomitant products included MOMETASONE FUROATE (ASMANEX), SALMETEROL XINAFOATE (SEREVENT), MIRABEGRON (MYRBETRIQ), ATORVASTATIN, TAMSULOSIN HYDROCHLORIDE (FLOMAX RELIEF), FAMPRIDINE (AMPYRA) and OCRELIZUMAB (OCREVUS). Treatment products include Tylenol.  Company Comment: Based on the current available information and temporal association between the use of the product and the start date of the events, a causal relationship cannot be excluded.   This case was linked to US-MODERNATX, INC.-MOD-2021-033043 (E2B Linked Report).   Most recent FOLLOW-UP information incorporated above includes: On 06-May-2021: Report from other manufacturer, additional AE.; Sender's Comments: Based on the current available information and temporal association between the use of the product and the start date of the events, a causal relationship cannot be excluded. US-MODERNATX, INC.-MOD-2021-033043:Second Dose Case
Sex: F
Vaccine: COVID19
Symptoms: Rash, Rash pruritic, Thermal burn
Clinical narrative: The rash was approximately 3 inches by 3 inches/The patient mentions it itches more than anything ever in her life; It was really really bothersome, miserable, and It looked like a burn; Rash in right arm after taking the second dose; This spontaneous case was reported by a consumer and describes the occurrence of RASH PRURITIC (The rash was approximately 3 inches by 3 inches/The patient mentions it itches more than anything ever in her life), THERMAL BURN (It was really really bothersome, miserable, and It looked like a burn) and RASH (Rash in right arm after taking the second dose) in an 80-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 027A21A) for COVID-19 vaccination.     No Medical History information was reported.   On an unknown date, the patient received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On an unknown date, received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) dosage was changed to 1 dosage form. On an unknown date, the patient experienced RASH PRURITIC (The rash was approximately 3 inches by 3 inches/The patient mentions it itches more than anything ever in her life), THERMAL BURN (It was really really bothersome, miserable, and It looked like a burn) and RASH (Rash in right arm after taking the second dose). The patient was treated with DIPHENHYDRAMINE HYDROCHLORIDE (BENADRYL [DIPHENHYDRAMINE HYDROCHLORIDE]) ongoing since an unknown date at an unspecified dose and frequency. At the time of the report, RASH PRURITIC (The rash was approximately 3 inches by 3 inches/The patient mentions it itches more than anything ever in her life), THERMAL BURN (It was really really bothersome, miserable, and It looked like a burn) and RASH (Rash in right arm after taking the second dose) outcome was unknown.            Treatment included Neosporin Cream and Benadryl  Action taken with mRNA-1273 in response to the event was Not Applicable
Age: 66.0
Sex: M
Vaccine: COVID19
Symptoms: Body temperature, Chills, Fatigue, Headache, Influenza like illness
Clinical narrative: Chills; Fatigues; Headache; Muscle pains; Flu-like symptoms off and on; fever; This spontaneous case was reported by a consumer and describes the occurrence of INFLUENZA LIKE ILLNESS (Flu-like symptoms off and on), CHILLS (Chills), FATIGUE (Fatigues), HEADACHE (Headache) and PYREXIA (fever) in a 66-year-old male patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch nos. 032L20A and 013L20A) for COVID-19 vaccination. The occurrence of additional non-serious events is detailed below.     Concurrent medical conditions included Asthma, Diabetes, Hypertension, Seizure, ADHD, Allergy NOS, Eczema, Neuropathic pain, Gout and Arthritis. Concomitant products included LISDEXAMFETAMINE MESILATE (VYVANSE) for ADHD, LEVOCETIRIZINE, FLUTICASONE PROPIONATE (FLONASE ALLERGY RELIEF) and AZELASTINE HCL for Allergy, MELOXICAM (MOBIC) for Arthritis, THEOPHYLLINE and FLUTICASONE PROPIONATE, SALMETEROL XINAFOATE (ADVAIR) for Asthma, LIRAGLUTIDE (VICTOZA) and METFORMIN for Diabetes, DUPILUMAB for Eczema, COLCHICINE for Gout, CANDESARTAN CILEXETIL (ATACAND) and DILTIAZEM HYDROCHLORIDE (DILTIAZEM CD) for Hypertension, GABAPENTIN for Neuropathic pain, LAMOTRIGINE for Seizure, HYDROCORTISONE VALERATE and TRIAMCINOLONE ACETONIDE for Skin disorder NOS.   On 19-Jan-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 14-Feb-2021, received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) dosage was changed to 2 dosage form. On 15-Feb-2021, the patient experienced INFLUENZA LIKE ILLNESS (Flu-like symptoms off and on) and PYREXIA (fever). On 14-Mar-2021, the patient experienced CHILLS (Chills), FATIGUE (Fatigues), HEADACHE (Headache) and MYALGIA (Muscle pains). The patient was treated with PARACETAMOL (TYLENOL) at a dose of UNK dosage form and IBUPROFEN at a dose of UNK dosage form. On 15-Mar-2021, MYALGIA (Muscle pains) had resolved. At the time of the report, INFLUENZA LIKE ILLNESS (Flu-like symptoms off and on) had not resolved and CHILLS (Chills), FATIGUE (Fatigues), HEADACHE (Headache) and PYREXIA (fever) outcome was unknown. Not Provided    DIAGNOSTIC RESULTS (normal ranges are provided in parenthesis if available): On 15-Feb-2021, Body temperature: 101.3 (High) 101.3F. On 16-Feb-2021, Body temperature: 101.1 (High) 101.1F. On 17-Feb-2021, Body temperature: 99f-100f (High) 99F-100F.
Age: 66.0
Sex: M
Vaccine: COVID19
Symptoms: Myalgia, Pyrexia
Clinical narrative: Chills; Fatigues; Headache; Muscle pains; Flu-like symptoms off and on; fever; This spontaneous case was reported by a consumer and describes the occurrence of INFLUENZA LIKE ILLNESS (Flu-like symptoms off and on), CHILLS (Chills), FATIGUE (Fatigues), HEADACHE (Headache) and PYREXIA (fever) in a 66-year-old male patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch nos. 032L20A and 013L20A) for COVID-19 vaccination. The occurrence of additional non-serious events is detailed below.     Concurrent medical conditions included Asthma, Diabetes, Hypertension, Seizure, ADHD, Allergy NOS, Eczema, Neuropathic pain, Gout and Arthritis. Concomitant products included LISDEXAMFETAMINE MESILATE (VYVANSE) for ADHD, LEVOCETIRIZINE, FLUTICASONE PROPIONATE (FLONASE ALLERGY RELIEF) and AZELASTINE HCL for Allergy, MELOXICAM (MOBIC) for Arthritis, THEOPHYLLINE and FLUTICASONE PROPIONATE, SALMETEROL XINAFOATE (ADVAIR) for Asthma, LIRAGLUTIDE (VICTOZA) and METFORMIN for Diabetes, DUPILUMAB for Eczema, COLCHICINE for Gout, CANDESARTAN CILEXETIL (ATACAND) and DILTIAZEM HYDROCHLORIDE (DILTIAZEM CD) for Hypertension, GABAPENTIN for Neuropathic pain, LAMOTRIGINE for Seizure, HYDROCORTISONE VALERATE and TRIAMCINOLONE ACETONIDE for Skin disorder NOS.   On 19-Jan-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 14-Feb-2021, received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) dosage was changed to 2 dosage form. On 15-Feb-2021, the patient experienced INFLUENZA LIKE ILLNESS (Flu-like symptoms off and on) and PYREXIA (fever). On 14-Mar-2021, the patient experienced CHILLS (Chills), FATIGUE (Fatigues), HEADACHE (Headache) and MYALGIA (Muscle pains). The patient was treated with PARACETAMOL (TYLENOL) at a dose of UNK dosage form and IBUPROFEN at a dose of UNK dosage form. On 15-Mar-2021, MYALGIA (Muscle pains) had resolved. At the time of the report, INFLUENZA LIKE ILLNESS (Flu-like symptoms off and on) had not resolved and CHILLS (Chills), FATIGUE (Fatigues), HEADACHE (Headache) and PYREXIA (fever) outcome was unknown. Not Provided    DIAGNOSTIC RESULTS (normal ranges are provided in parenthesis if available): On 15-Feb-2021, Body temperature: 101.3 (High) 101.3F. On 16-Feb-2021, Body temperature: 101.1 (High) 101.1F. On 17-Feb-2021, Body temperature: 99f-100f (High) 99F-100F.
Age: 67.0
Sex: F
Vaccine: COVID19
Symptoms: Headache, Urticaria
Clinical narrative: Welts on face; Headache; This spontaneous case was reported by a pharmacist and describes the occurrence of URTICARIA (Welts on face) and HEADACHE (Headache) in a 67-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 024C21A) for COVID-19 vaccination.     NO MEDICAL HISTORY RECORDED.  Concomitant products included ATENOLOL, OLANZAPINE, ESTRADIOL and VERAPAMIL HYDROCHLORIDE (VERAPAMIL EG) for an unknown indication.    On 01-May-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On an unknown date, the patient experienced URTICARIA (Welts on face) and HEADACHE (Headache). The patient was treated with DIPHENHYDRAMINE HYDROCHLORIDE (BENADRYL [DIPHENHYDRAMINE HYDROCHLORIDE]) ongoing since an unknown date at a dose of 1 dosage form. At the time of the report, URTICARIA (Welts on face) and HEADACHE (Headache) had not resolved.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.   For mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular), the reporter did not provide any causality assessments.   Treatment information was not provided
Age: 54.0
Sex: M
Vaccine: COVID19
Symptoms: Pain in extremity, Plantar fascial fibromatosis, Plantar fasciitis, X-ray
Clinical narrative: He had a ball in the left plantar arch; Pain was so great that he cannot work/had been intensifying, particularly after the second dose; Patient began to have pain in the plantar arch; This spontaneous case was reported by a consumer (subsequently medically confirmed) and describes the occurrence of PAIN IN EXTREMITY (Pain was so great that he cannot work/had been intensifying, particularly after the second dose), PLANTAR FASCIITIS (Patient began to have pain in the plantar arch) and PLANTAR FASCIAL FIBROMATOSIS (He had a ball in the left plantar arch) in a 54-year-old male patient who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     Concomitant products included INSULIN for an unknown indication.   On 10-Mar-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 09-Apr-2021, received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) dosage was changed to 1 dosage form. In March 2021, the patient experienced PAIN IN EXTREMITY (Pain was so great that he cannot work/had been intensifying, particularly after the second dose) and PLANTAR FASCIITIS (Patient began to have pain in the plantar arch). On an unknown date, the patient experienced PLANTAR FASCIAL FIBROMATOSIS (He had a ball in the left plantar arch). The patient was treated with NAPROXEN at an unspecified dose and frequency. At the time of the report, PAIN IN EXTREMITY (Pain was so great that he cannot work/had been intensifying, particularly after the second dose) and PLANTAR FASCIITIS (Patient began to have pain in the plantar arch) had not resolved and PLANTAR FASCIAL FIBROMATOSIS (He had a ball in the left plantar arch) outcome was unknown.      DIAGNOSTIC RESULTS (normal ranges are provided in parenthesis if available): On an unknown date, X-ray: normal (normal) found nothing.         Treatment medication included Naproxen.  Action taken with mRNA-1273 in response to the events was not applicable.   This case was linked to MOD-2021-101860 (Patient Link).
Age: 62.0
Sex: F
Vaccine: COVID19
Symptoms: Arthralgia, Erythema, Fatigue, Hypersensitivity, Myalgia
Clinical narrative: Tiredness; hyper sensitive reaction; achiness,ankle pain and top of the foot is painful / sore arm; itchy rash(red) all over trunk(front/back)and underarms; bleeding rash; rash moved to her chest ( including breast and nipples) as well as to the back of her head; Shoulder joint pain; red; raised bumps not welty; feel itchy in her back and underarm; This spontaneous case was reported by a consumer and describes the occurrence of PRURITUS (feel itchy in her back and underarm), PURPURA (bleeding rash), ERYTHEMA (red), RASH PAPULAR (raised bumps not welty) and RASH (rash moved to her chest ( including breast and nipples) as well as to the back of her head) in a 62-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 036B21A) for COVID-19 vaccination. The occurrence of additional non-serious events is detailed below.     No medical history was provided by reporter.  Concurrent medical conditions included Asthma, Allergy to antibiotic and Allergy to animals. Concomitant products included OMEPRAZOLE for GERD, MULTIVITAMIN [VITAMINS NOS] for an unknown indication.    On 07-Apr-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 08-Apr-2021, the patient experienced PRURITUS (feel itchy in her back and underarm), ERYTHEMA (red) and RASH PAPULAR (raised bumps not welty). On 09-Apr-2021, the patient experienced PURPURA (bleeding rash), RASH (rash moved to her chest ( including breast and nipples) as well as to the back of her head), ARTHRALGIA (Shoulder joint pain) and RASH PRURITIC (itchy rash(red) all over trunk(front/back)and underarms). On 10-Apr-2021, the patient experienced MYALGIA (achiness,ankle pain and top of the foot is painful / sore arm). On an unknown date, the patient experienced FATIGUE (Tiredness) and HYPERSENSITIVITY (hyper sensitive reaction). The patient was treated with IBUPROFEN at a dose of 1 dosage form; DIPHENHYDRAMINE HYDROCHLORIDE (BENADRYL [DIPHENHYDRAMINE HYDROCHLORIDE]) at a dose of 1 dosage form and CORTISONE at a dose of 1 dosage form. At the time of the report, PRURITUS (feel itchy in her back and underarm), PURPURA (bleeding rash), ERYTHEMA (red), RASH PAPULAR (raised bumps not welty), RASH (rash moved to her chest ( including breast and nipples) as well as to the back of her head), ARTHRALGIA (Shoulder joint pain), MYALGIA (achiness,ankle pain and top of the foot is painful / sore arm) and HYPERSENSITIVITY (hyper sensitive reaction) had not resolved and FATIGUE (Tiredness) and RASH PRURITIC (itchy rash(red) all over trunk(front/back)and underarms) outcome was unknown. Not Provided      The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.   For mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular), the reporter did not provide any causality assessments.   This case was linked to MOD-2021-267089 (Patient Link).   Most recent FOLLOW-UP information incorporated above includes: On 26-Jul-2021: Significant Followup Patient historical condition and demographic details was updated.
Age: 62.0
Sex: F
Vaccine: COVID19
Symptoms: Pruritus, Purpura, Rash, Rash papular, Rash pruritic
Clinical narrative: Tiredness; hyper sensitive reaction; achiness,ankle pain and top of the foot is painful / sore arm; itchy rash(red) all over trunk(front/back)and underarms; bleeding rash; rash moved to her chest ( including breast and nipples) as well as to the back of her head; Shoulder joint pain; red; raised bumps not welty; feel itchy in her back and underarm; This spontaneous case was reported by a consumer and describes the occurrence of PRURITUS (feel itchy in her back and underarm), PURPURA (bleeding rash), ERYTHEMA (red), RASH PAPULAR (raised bumps not welty) and RASH (rash moved to her chest ( including breast and nipples) as well as to the back of her head) in a 62-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 036B21A) for COVID-19 vaccination. The occurrence of additional non-serious events is detailed below.     No medical history was provided by reporter.  Concurrent medical conditions included Asthma, Allergy to antibiotic and Allergy to animals. Concomitant products included OMEPRAZOLE for GERD, MULTIVITAMIN [VITAMINS NOS] for an unknown indication.    On 07-Apr-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 08-Apr-2021, the patient experienced PRURITUS (feel itchy in her back and underarm), ERYTHEMA (red) and RASH PAPULAR (raised bumps not welty). On 09-Apr-2021, the patient experienced PURPURA (bleeding rash), RASH (rash moved to her chest ( including breast and nipples) as well as to the back of her head), ARTHRALGIA (Shoulder joint pain) and RASH PRURITIC (itchy rash(red) all over trunk(front/back)and underarms). On 10-Apr-2021, the patient experienced MYALGIA (achiness,ankle pain and top of the foot is painful / sore arm). On an unknown date, the patient experienced FATIGUE (Tiredness) and HYPERSENSITIVITY (hyper sensitive reaction). The patient was treated with IBUPROFEN at a dose of 1 dosage form; DIPHENHYDRAMINE HYDROCHLORIDE (BENADRYL [DIPHENHYDRAMINE HYDROCHLORIDE]) at a dose of 1 dosage form and CORTISONE at a dose of 1 dosage form. At the time of the report, PRURITUS (feel itchy in her back and underarm), PURPURA (bleeding rash), ERYTHEMA (red), RASH PAPULAR (raised bumps not welty), RASH (rash moved to her chest ( including breast and nipples) as well as to the back of her head), ARTHRALGIA (Shoulder joint pain), MYALGIA (achiness,ankle pain and top of the foot is painful / sore arm) and HYPERSENSITIVITY (hyper sensitive reaction) had not resolved and FATIGUE (Tiredness) and RASH PRURITIC (itchy rash(red) all over trunk(front/back)and underarms) outcome was unknown. Not Provided      The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.   For mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular), the reporter did not provide any causality assessments.   This case was linked to MOD-2021-267089 (Patient Link).   Most recent FOLLOW-UP information incorporated above includes: On 26-Jul-2021: Significant Followup Patient historical condition and demographic details was updated.
Age: 57.0
Sex: F
Vaccine: COVID19
Symptoms: Chills, Dysgeusia
Clinical narrative: got metallic taste in mouth that went straight to tongue; Chills; This spontaneous case was reported by a consumer and describes the occurrence of DYSGEUSIA (got metallic taste in mouth that went straight to tongue) and CHILLS (Chills) in a 57-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 046A21A) for COVID-19 vaccination.     The patient's past medical history included Anaphylactic reaction (random anaphylactic reactions). Concurrent medical conditions included Asthma and Taste altered (tongue gets really funny when eats acidic things, and things like walnuts).    On 25-Mar-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 25-Mar-2021, the patient experienced DYSGEUSIA (got metallic taste in mouth that went straight to tongue) and CHILLS (Chills). At the time of the report, DYSGEUSIA (got metallic taste in mouth that went straight to tongue) had resolved and CHILLS (Chills) outcome was unknown.        mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) dosing remained unchanged.       No concomitant and treatment were reported.   This case was linked to MOD-2021-101854 (Patient Link).
Sex: M
Vaccine: COVID19
Symptoms: COVID-19, Feeling abnormal, Pain in extremity
Clinical narrative: This spontaneous case was reported by a consumer and describes the occurrence of FEELING ABNORMAL (felt crappy), PAIN IN EXTREMITY (sore arm) and COVID-19 (Tested positive for Covid-19) in a 60-year-old male patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 045B21A) for COVID-19 vaccination.  Concurrent medical conditions included COVID-19 since 28-Apr-2021. Concomitant products included BISOPROLOL FUMARATE, HYDROCHLOROTHIAZIDE (BISOPROLOL /HCTZ) for Hypertension. On 21-Apr-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 27-Apr-2021, the patient experienced FEELING ABNORMAL (felt crappy) and PAIN IN EXTREMITY (sore arm). On 28-Apr-2021, the patient experienced COVID-19 (Tested positive for Covid-19). At the time of the report, FEELING ABNORMAL (felt crappy), PAIN IN EXTREMITY (sore arm) and COVID-19 (Tested positive for Covid-19) outcome was unknown.    DIAGNOSTIC RESULTS (normal ranges are provided in parenthesis if available): On 28-Apr-2021, COVID-19: other (Positive) Positive. The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown. No treatment information was provided.
Age: 59.0
Sex: F
Vaccine: COVID19
Symptoms: Limb discomfort, Vaccination site pain, Vaccination site pruritus, Vaccination site rash
Clinical narrative: Redish/pinkish/hot rash; Soreness returned; A little itch; Tenderness/soreness (at injection site); This spontaneous case was reported by a consumer and describes the occurrence of LIMB DISCOMFORT (Soreness returned), VACCINATION SITE PRURITUS (A little itch), VACCINATION SITE PAIN (Tenderness/soreness (at injection site)) and VACCINATION SITE RASH (Redish/pinkish/hot rash) in a 59-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     No Medical History information was reported.    On 23-Apr-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 23-Apr-2021, the patient experienced VACCINATION SITE PRURITUS (A little itch) and VACCINATION SITE PAIN (Tenderness/soreness (at injection site)). On 01-May-2021, the patient experienced LIMB DISCOMFORT (Soreness returned). On an unknown date, the patient experienced VACCINATION SITE RASH (Redish/pinkish/hot rash). At the time of the report, LIMB DISCOMFORT (Soreness returned), VACCINATION SITE PRURITUS (A little itch), VACCINATION SITE PAIN (Tenderness/soreness (at injection site)) and VACCINATION SITE RASH (Redish/pinkish/hot rash) had not resolved.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.       No concomitant and treatment information was reported by the reporter.   Most recent FOLLOW-UP information incorporated above includes: On 03-Jun-2021: Outcome of the event is updated
Sex: M
Vaccine: COVID19
Symptoms: Eye swelling, Swelling, Swelling face
Clinical narrative: swelling of his eyes; swelling of his face; "Bumps" on his body; This spontaneous case was reported by a consumer and describes the occurrence of EYE SWELLING (swelling of his eyes), SWELLING FACE (swelling of his face) and SWELLING ("Bumps" on his body) in a male patient of an unknown age who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     No Medical History information was reported.    On 30-Apr-2021, the patient received dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On an unknown date, the patient experienced EYE SWELLING (swelling of his eyes), SWELLING FACE (swelling of his face) and SWELLING ("Bumps" on his body). At the time of the report, EYE SWELLING (swelling of his eyes), SWELLING FACE (swelling of his face) and SWELLING ("Bumps" on his body) outcome was unknown. Not Provided      The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.       Concomitant product use was not provided by the reporter. No treatment information was provided.
Age: 57.0
Sex: F
Vaccine: COVID19
Symptoms: Chills, Dysgeusia, Gait disturbance, Lethargy
Clinical narrative: metallic acidic taste in my mouth; felt lethargic; my gait was off balance; Chills; This spontaneous case was reported by a consumer and describes the occurrence of DYSGEUSIA (metallic acidic taste in my mouth), LETHARGY (felt lethargic), GAIT DISTURBANCE (my gait was off balance) and CHILLS (Chills) in a 57-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch nos. 041B21A and 046A21A) for COVID-19 vaccination.     No medical history reported.  Concurrent medical conditions included Asthma, Anaphylactic reaction (Random anaphylactic reactions), Food allergy (Patients tongue gets funny after consuming acidic things, and things like walnuts.) and Allergy to nuts (Patients tongue gets funny after consuming acidic things, and things like walnuts.).   On 25-Mar-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 19-Apr-2021, received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) dosage was changed to 1 dosage form. On 19-Apr-2021, the patient experienced DYSGEUSIA (metallic acidic taste in my mouth), LETHARGY (felt lethargic), GAIT DISTURBANCE (my gait was off balance) and CHILLS (Chills). At the time of the report, DYSGEUSIA (metallic acidic taste in my mouth), LETHARGY (felt lethargic), GAIT DISTURBANCE (my gait was off balance) and CHILLS (Chills) outcome was unknown.            No concomitant medications listed.  No treatment medication was reported.   This case was linked to MOD-2021-101849 (Patient Link).
Age: 16.0
Sex: M
Vaccine: COVID19
Symptoms: Off label use, Product administered to patient of inappropriate age
Clinical narrative: 16 year old received Moderna vaccine; Vaccine given off label; This spontaneous case was reported by a pharmacist and describes the occurrence of PRODUCT ADMINISTERED TO PATIENT OF INAPPROPRIATE AGE (16 year old received Moderna vaccine) and OFF LABEL USE (Vaccine given off label) in a 16-year-old male patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch nos. 018B21A and 031B21A) for COVID-19 vaccination.     No Medical History information was reported.   On 27-Apr-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 25-May-2021, received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) dosage was changed to 1 dosage form. On 27-Apr-2021, the patient experienced PRODUCT ADMINISTERED TO PATIENT OF INAPPROPRIATE AGE (16 year old received Moderna vaccine) and OFF LABEL USE (Vaccine given off label). On 27-Apr-2021, OFF LABEL USE (Vaccine given off label) had resolved. On 25-May-2021, PRODUCT ADMINISTERED TO PATIENT OF INAPPROPRIATE AGE (16 year old received Moderna vaccine) had resolved. Not Provided      For mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular), the reporter did not provide any causality assessments.   No concomitant medications was reported. No treatment information was provided by the reporter.   Most recent FOLLOW-UP information incorporated above includes: On 03-Jun-2021: Additional information received on 03-JUN-2021 contains Significant follow up: Added Patient Demographics, Suspect Drug Details (Onset date, 2nd Dose date), Vaccination facility Details, New Event Term Added.
Age: 78.0
Sex: F
Vaccine: COVID19
Symptoms: Malaise, Sinusitis
Clinical narrative: Symptoms of a Sinus Infection; Did Not Feel Good; This spontaneous case was reported by a consumer and describes the occurrence of SINUSITIS (Symptoms of a Sinus Infection) and MALAISE (Did Not Feel Good) in a 78-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch nos. 026B21A and 036A21A) for COVID-19 vaccination.     No Medical History information was reported.   On 05-Mar-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 02-Apr-2021, received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) dosage was changed to 1 dosage form. On 02-Apr-2021, the patient experienced SINUSITIS (Symptoms of a Sinus Infection) and MALAISE (Did Not Feel Good). On 05-Apr-2021, SINUSITIS (Symptoms of a Sinus Infection) and MALAISE (Did Not Feel Good) had resolved. Not Provided          No relevant concomitant medications were reported. No treatment information was reported. Action taken with mRNA-1273 in response to the events was not applicable.    This case was linked to MOD-2021-037141 (Patient Link).
Sex: U
Vaccine: COVID19
Symptoms: Inappropriate schedule of product administration
Clinical narrative: received my 2nd dose 19 days after my first; This spontaneous case was reported by a consumer and describes the occurrence of INAPPROPRIATE SCHEDULE OF PRODUCT ADMINISTRATION (received my 2nd dose 19 days after my first) in a patient of an unknown age and gender who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     No Medical History information was reported.    On an unknown date, the patient received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On an unknown date, the patient experienced INAPPROPRIATE SCHEDULE OF PRODUCT ADMINISTRATION (received my 2nd dose 19 days after my first). At the time of the report, INAPPROPRIATE SCHEDULE OF PRODUCT ADMINISTRATION (received my 2nd dose 19 days after my first) had resolved.            No concomitant medications were reported.
Age: 54.0
Sex: M
Vaccine: COVID19
Symptoms: Plantar fascial fibromatosis, Plantar fasciitis, X-ray
Clinical narrative: Ball in the left plantar arch; Pain in the plantar arch; This spontaneous case was reported by a consumer and describes the occurrence of PLANTAR FASCIITIS (Pain in the plantar arch) and PLANTAR FASCIAL FIBROMATOSIS (Ball in the left plantar arch) in a 54-year-old male patient who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     Concomitant products included INSULIN for an unknown indication.    On 10-Mar-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 11-Mar-2021, the patient experienced PLANTAR FASCIITIS (Pain in the plantar arch). On an unknown date, the patient experienced PLANTAR FASCIAL FIBROMATOSIS (Ball in the left plantar arch). The patient was treated with NAPROXEN at an unspecified dose and frequency. At the time of the report, PLANTAR FASCIITIS (Pain in the plantar arch) and PLANTAR FASCIAL FIBROMATOSIS (Ball in the left plantar arch) had not resolved.      DIAGNOSTIC RESULTS (normal ranges are provided in parenthesis if available): In April 2021, X-ray: normal (normal) No abnormalities.     The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.       This case was linked to MOD-2021-101847 (Patient Link).
Age: 35.0
Sex: F
Vaccine: COVID19
Symptoms: Cough, Feeling abnormal, Headache, Influenza like illness, Oropharyngeal pain
Clinical narrative: sore throat; feeling very bad; runny nose; cough; flu like symptoms; headache; felt pain the arm,arm hurt; This spontaneous case was reported by a patient and describes the occurrence of PAIN IN EXTREMITY (felt pain the arm,arm hurt), OROPHARYNGEAL PAIN (sore throat), FEELING ABNORMAL (feeling very bad), RHINORRHOEA (runny nose) and COUGH (cough) in a 35-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 031B21A) for COVID-19 vaccination. The occurrence of additional non-serious events is detailed below.     No Medical History information was reported.    On 07-Apr-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 07-Apr-2021, the patient experienced PAIN IN EXTREMITY (felt pain the arm,arm hurt) and HEADACHE (headache). On an unknown date, the patient experienced OROPHARYNGEAL PAIN (sore throat), FEELING ABNORMAL (feeling very bad), RHINORRHOEA (runny nose), COUGH (cough) and INFLUENZA LIKE ILLNESS (flu like symptoms). At the time of the report, PAIN IN EXTREMITY (felt pain the arm,arm hurt), OROPHARYNGEAL PAIN (sore throat), FEELING ABNORMAL (feeling very bad), RHINORRHOEA (runny nose), COUGH (cough), INFLUENZA LIKE ILLNESS (flu like symptoms) and HEADACHE (headache) outcome was unknown. Not Provided      The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.       No concomitant medications were reported. No corrective treatment was reported by the patient.
Age: 35.0
Sex: F
Vaccine: COVID19
Symptoms: Pain in extremity, Rhinorrhoea
Clinical narrative: sore throat; feeling very bad; runny nose; cough; flu like symptoms; headache; felt pain the arm,arm hurt; This spontaneous case was reported by a patient and describes the occurrence of PAIN IN EXTREMITY (felt pain the arm,arm hurt), OROPHARYNGEAL PAIN (sore throat), FEELING ABNORMAL (feeling very bad), RHINORRHOEA (runny nose) and COUGH (cough) in a 35-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 031B21A) for COVID-19 vaccination. The occurrence of additional non-serious events is detailed below.     No Medical History information was reported.    On 07-Apr-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 07-Apr-2021, the patient experienced PAIN IN EXTREMITY (felt pain the arm,arm hurt) and HEADACHE (headache). On an unknown date, the patient experienced OROPHARYNGEAL PAIN (sore throat), FEELING ABNORMAL (feeling very bad), RHINORRHOEA (runny nose), COUGH (cough) and INFLUENZA LIKE ILLNESS (flu like symptoms). At the time of the report, PAIN IN EXTREMITY (felt pain the arm,arm hurt), OROPHARYNGEAL PAIN (sore throat), FEELING ABNORMAL (feeling very bad), RHINORRHOEA (runny nose), COUGH (cough), INFLUENZA LIKE ILLNESS (flu like symptoms) and HEADACHE (headache) outcome was unknown. Not Provided      The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.       No concomitant medications were reported. No corrective treatment was reported by the patient.
Age: 59.0
Sex: F
Vaccine: COVID19
Symptoms: Nasal congestion, Nasopharyngitis, Sinus congestion
Clinical narrative: has a cold; congestion; sinus issues; This spontaneous case was reported by a consumer and describes the occurrence of NASOPHARYNGITIS (has a cold), NASAL CONGESTION (congestion) and SINUS CONGESTION (sinus issues) in a 59-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 019B21A) for COVID-19 vaccination.     No Medical History information was reported.    On 06-Apr-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 06-Apr-2021, the patient experienced NASOPHARYNGITIS (has a cold), NASAL CONGESTION (congestion) and SINUS CONGESTION (sinus issues). At the time of the report, NASOPHARYNGITIS (has a cold), NASAL CONGESTION (congestion) and SINUS CONGESTION (sinus issues) outcome was unknown. Not Provided      The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.       No concomitant medications were reported. No laboratory details were  provided. No treatment medications were reported.
Age: 41.0
Sex: F
Vaccine: COVID19
Symptoms: Blood glucose, Dizziness, Dysarthria, Dyspnoea, SARS-CoV-2 test
Clinical narrative: Dizziness; shortness of breath; Slurred speech; This spontaneous case was reported by a consumer and describes the occurrence of DIZZINESS (Dizziness), DYSPNOEA (shortness of breath) and DYSARTHRIA (Slurred speech) in a 41-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 027A21A) for COVID-19 vaccination.     The patient's past medical history included COVID-19 on 08-Dec-2020. Concurrent medical conditions included Drug allergy (Codeine-Vomiting), Blood pressure high and Anxiety. Concomitant products included AMLODIPINE and ESCITALOPRAM OXALATE (LEXAPRO) for an unknown indication.    On 26-Mar-2021 at 10:00 AM, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 26-Mar-2021, the patient experienced DIZZINESS (Dizziness), DYSPNOEA (shortness of breath) and DYSARTHRIA (Slurred speech). At the time of the report, DIZZINESS (Dizziness), DYSPNOEA (shortness of breath) and DYSARTHRIA (Slurred speech) had not resolved.      DIAGNOSTIC RESULTS (normal ranges are provided in parenthesis if available): On 12-Aug-2020, SARS-CoV-2 test: positive (Positive) Nasal swab. On 26-Mar-2021, Blood glucose: 73 (Inconclusive) Blood sugar drop.     The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.       Patient had EEG and MRI. Treatment includes Juice and Candy.   This case was linked to MOD-2021-101869 (Patient Link).   Most recent FOLLOW-UP information incorporated above includes: On 08-Jun-2021: Follow-up information received on 08-JUN-2021; Reporter's details updated, Patient's demographic details, Patient medical history, Lab data updated. Concomitant medications updated. Event details and outcome updated. On 02-Jul-2021: Follow-up received and contains non significant information. On 19-Jul-2021: Follow up received and contain non significant information.
Age: 78.0
Sex: M
Vaccine: COVID19, UNK
Symptoms: Breast pain, Sensory disturbance, Tenderness
Clinical narrative: pain in the right breast; sensitivity of the nipple; sensitive and tender; This spontaneous case was reported by a consumer (subsequently medically confirmed) and describes the occurrence of BREAST PAIN (pain in the right breast), SENSORY DISTURBANCE (sensitivity of the nipple) and TENDERNESS (sensitive and tender) in a 78-year-old male patient who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.    Co-suspect product included non-company product SPIRONOLACTONE for an unknown indication.    No Medical History information was reported.   On an unknown date, the patient received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form On an unknown date, received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) dosage was changed to 1 dosage form. and SPIRONOLACTONE (unknown route) dosage form. On an unknown date, the patient experienced BREAST PAIN (pain in the right breast), SENSORY DISTURBANCE (sensitivity of the nipple) and TENDERNESS (sensitive and tender). At the time of the report, BREAST PAIN (pain in the right breast), SENSORY DISTURBANCE (sensitivity of the nipple) and TENDERNESS (sensitive and tender) had not resolved.            Action taken with mRNA-1273 in response to the events was not Applicable. Concomitant and treatment information not provided   This case was linked to US-MODERNATX, INC.-MOD-2021-101841 (E2B Linked Report).   Most recent FOLLOW-UP information incorporated above includes: On 03-Jun-2021: Follow-up information received on 03-JUN-2021 contains non-significant information.; Sender's Comments:  US-MODERNATX, INC.-MOD-2021-101841:cross linked case
Age: 72.0
Sex: F
Vaccine: COVID19
Symptoms: Myalgia
Clinical narrative: Sore arm; This spontaneous case was reported by a consumer and describes the occurrence of MYALGIA (Sore arm) in a 72-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch nos. 012M20A and 025L20A) for COVID-19 vaccination.     No medical history was provided.    On 16-Jan-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 13-Feb-2021, received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) dosage was changed to 1 dosage form. On 16-Jan-2021, the patient experienced MYALGIA (Sore arm). At the time of the report, MYALGIA (Sore arm) outcome was unknown. Not Provided      For mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular), the reporter did not provide any causality assessments.   No concomitant medications listed.  Patient taking muscle relaxants for treatment.   This case was linked to US-MODERNATX, INC.-MOD-2021-101893 (E2B Linked Report).; Sender's Comments:  US-MODERNATX, INC.-MOD-2021-101893:case for wife(dose1)
Age: 35.0
Sex: F
Vaccine: COVID19
Symptoms: Product storage error
Clinical narrative: This spontaneous case was reported by a pharmacist and describes the occurrence of PRODUCT STORAGE ERROR (Improper preparation of thawed vial) in a 35-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 016B21A) for COVID-19 vaccination. No Medical History information was reported. On an unknown date, the patient received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 21-Apr-2021, the patient experienced PRODUCT STORAGE ERROR (Improper preparation of thawed vial). On 21-Apr-2021, PRODUCT STORAGE ERROR (Improper preparation of thawed vial) outcome was unknown. For mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown), the reporter did not provide any causality assessments. No concomitant and treatment medications were provided by reporter.
Age: 84.0
Sex: F
Vaccine: COVID19
Symptoms: Hypoaesthesia
Clinical narrative: Numb Fingers on her Left hand (Not Injected Arm); This spontaneous case was reported by a consumer and describes the occurrence of HYPOAESTHESIA (Numb Fingers on her Left hand (Not Injected Arm)) in an 84-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 008B21A) for COVID-19 vaccination.     No Medical History information was reported.    On 30-Apr-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 01-May-2021, the patient experienced HYPOAESTHESIA (Numb Fingers on her Left hand (Not Injected Arm)). At the time of the report, HYPOAESTHESIA (Numb Fingers on her Left hand (Not Injected Arm)) had not resolved. Not Provided      The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.       No concomitant medications were reported. Treatment information was not provided.    Reporter did not allow further contact